Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US7906550B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Feb 6, 2008 |
| Grant date | Mar 15, 2011 |
| Priority date | — |
| Expiry date | Feb 6, 2028 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P41/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to compounds of formula I:or pharmaceutically acceptable salts thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are useful as antiviral agents. The invention further relates to pharmaceutically acceptable compositions comprising said compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a pharmaceutical composition comprising a compound of this invention.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.